[1] Stephens C,Lucena MI,Andrade RJ. Genetic variations in drug-induced liver injury(DILI):resolving the puzzle. Front Genet,2012,16(11):253-253. [2] Nathwani RA,Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis,2006,10(2):207-217. [3] Devarbhavi H,Dierkhising R,Kremers WK,et al. Single-center experience with drug-induced liver injury from India:causes,outcome,prognosis,and predictors of mortality. Am J Gastroenterol,2010,105:2396-2404. [4] Au JS,Navarro VJ,Rossi S. Review article: Drug-induced liver injury-its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther,2011,34:11-20. [5] 中华消化专业委员会. 急性药物性肝损伤诊治建议(草案). 中华消化杂志,2007,27(11):765-767. [6] Bagheri H,Michel F,Lapeyre-Mestre M,et al. Detection and incidence of drug-induced liver injuries in hospital:a prospective analysis from laboratory signals. Br J Clin Pharmacol,2000,50:479-484. [7] Aithal GP,Watkins PB,Andrade RJ,et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther,2011,89:806-815. [8] Au JS,Navarro VJ,Rossi S. Review article:drug-induced liver injury-its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther,2011,34:11-20. [9] 李晨,辛绍杰,游绍莉. 中草药致肝损害研究进展. 实用肝脏病杂志,2013,16(6):278-281. [10] García-Cortés M,Lucena MI,Pachkoria K,et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug induced liver injury. Aliment Pharmacol Ther,2008,27:780-789. [11] Takikawa H,Murata Y,Horiike N,et al. Drug induced liver injury in Japan:An analysis of 1676 cases between 1997 and 2006. Hepatol Res,2009,39: 427-431. [12] 魏傲,石小枫. 药物性肝损害344例临床分析. 现代医药卫生,2010,26:3528-3530. [13] Xu HM,Chen Y,Xu J,et al. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase. World J Gastroenterol,2012,18(41):5972-5978. [14] 中华医学会消化病分会肝胆疾病协作组.全国多中心急性药物性肝损伤住院病例调研分析. 中华消化杂志,2007,27(7):439-442. [15] 苏尊玮,廖宗琳. 中药与西药所致药物性肝损伤的临床对比分析. 实用肝脏病杂志,2009,12(2):137-138. [16] Fontana RJ,Watkins PB,Bonkovsky HL,et al. Drug-induced liver injury network(DILIN) prospective study:rationale,design and conduct. Drug Saf,2009,32:55-68. [17] Fontana RJ,Seeff LB,Andrade RJ,et al. Standardization of nomenclature and causality assessment in drug-induced liver injury:summary of a clinical research workshop. Hepatology,2010,52:730-742. [18] Kato H,Horita N,Miyazawa N,et al. Risk factors for liver injury with an elevated serum bilirubin concentration caused by antituberculous drugs. Intern Med,2013,52(19):2209-22014. [19] 滕光菊,孙颖,常彬霞,等. 418例药物性肝损害临床特征及预后分析. 肝脏,2013,18:11-14. [20] Wree A,Dechêne A,Herzer K,et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion,2011,84(1):54-59. [21] 周健,刘黎,黄丽雯,等. 牛磺熊去氧胆酸治疗非酒精性脂肪肝疗效观察. 实用肝脏病杂志,2014,17(1):80-81. [22] Anwar S,Jawad H,Sawsan S. A study of the effect of Nigella sativa (Black seeds) in isoniazid (INH)-induced hepatotoxicity in rabbits. Indian J Pharmacol,2012,44(6):678-682. [23] Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov,2005,4:489-499. |